9月1日，泽璟制药涨5.32%，截至发稿，报107.44元/股，成交2.09亿元，换手率0.74%，总市值284.40亿 元。 截至发稿，李涛累计任职时间1年251天，现任基金资产总规模2924.58万元，任职期间最佳基金回报 12.22%， 任职期间最差基金回报11.08%。 资料显示，苏州泽璟生物制药股份有限公司位于江苏省昆山市玉山镇晨丰路262号，成立日期2009年3月 18日，上市日期2020年1月23日，公司主营业务涉及化学新药及生物新药的研发、生产及销售。主营业 务收入构成为：药品99.97%，医药中间体及原辅料0.02%，资产租赁0.00%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 从基金十大重仓股角度 数据显示，中国路博迈基金旗下1只基金重仓泽璟制药。路博迈中国医疗健康股票发起A（020142）二 季度持有股数9900股，占基金净值比例为3.64%，位居第十大重仓股。根据测算，今日浮盈赚取约5.38 万元。 路博迈中国医疗健康股票发起A（02014 ...

Core Viewpoint - The report highlights a significant institutional ownership in the company, with a total of 14 institutional investors holding 3.94 billion shares, representing 51.87% of the total share capital as of August 25, 2025 [1] Group 1: Institutional Ownership - A total of 14 institutional investors disclosed their holdings in the company, with a combined shareholding of 3.94 billion shares, accounting for 51.87% of the total share capital [1] - The top ten institutional investors collectively hold 51.84% of the shares, with a decrease of 3.21 percentage points compared to the previous quarter [1] Group 2: Public Fund Holdings - Two public funds increased their holdings during this period, while three public funds reduced their holdings, with a decrease rate of 0.24% [2] - Four new public funds disclosed their holdings this period, while seven public funds were not disclosed compared to the previous quarter [2] Group 3: Insurance Capital Holdings - One insurance capital entity, China Life Insurance Co., Ltd., reported a slight decrease in holdings during this period [2]